Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (University of North Carolina at Chapel Hill)
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal, Intranasal
01
Overview
Fecal microbiota transplantation (FMT) is an investigational biologic therapy being studied by the University of North Carolina, Chapel Hill for the treatment of severe and enduring anorexia nervosa. The therapy involves the administration of a healthy donor fecal microbiota preparation, sourced from OpenBiome (FMP30), into the upper gastrointestinal tract via a nasogastric tube. As a live biotherapeutic product, FMT aims to modulate the patient's gut microbiota and the associated microbiome-gut-brain axis. The therapeutic goal is to positively influence weight regulation, metabolism, and anxiety behaviors associated with the eating disorder. The research is being conducted as an open-label pilot trial to evaluate the safety, feasibility, and tolerability of this approach.
- Other names
- Fecal microbiota transplantFMT
Beyond the preview
Go deeper on fecal microbiota transplantation (University of North Carolina at Chapel Hill).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (University of North Carolina at Chapel Hill).